CD19 and acute lymphoblastic leukemia: CD19-targeted CAR T cells were found to induce complete remission of disease in up to 90% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) who had an expected complete response rate to chemotherapy of 30% (1).